000			01410 a2200397 4500
005			20250514005832.0
264		0	_c20010927
008			200109s 0 0 eng d
022			_a0893-0341
024	7		_a10.1097/00002093-200107000-00008 _2doi
040			_aNLM _beng _cNLM
100	1		_aKnopman, D
245	0	0	_aAn open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. _h[electronic resource]
260			_bAlzheimer disease and associated disorders _c
300			_a162-5 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAlzheimer Disease _xdrug therapy
650	0	4	_aBetaine _xadverse effects
650	0	4	_aCognition Disorders _xdrug therapy
650	0	4	_aDisease Progression
650	0	4	_aFemale
650	0	4	_aGastrointestinal Agents _xadverse effects
650	0	4	_aHomocysteine _xmetabolism
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMental Status Schedule
650	0	4	_aMiddle Aged
650	0	4	_aRisk Factors
650	0	4	_aTreatment Outcome
700	1		_aPatterson, M
773	0		_tAlzheimer disease and associated disorders _gvol. 15 _gno. 3 _gp. 162-5
856	4	0	_uhttps://doi.org/10.1097/00002093-200107000-00008 _zAvailable from publisher's website
999			_c11447221 _d11447221